<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282824</url>
  </required_header>
  <id_info>
    <org_study_id>18-001776</org_study_id>
    <secondary_id>NCI-2019-04437</secondary_id>
    <secondary_id>18-001776</secondary_id>
    <nct_id>NCT04282824</nct_id>
  </id_info>
  <brief_title>Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer</brief_title>
  <acronym>MSG PSMA PET</acronym>
  <official_title>Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in&#xD;
      decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific&#xD;
      membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells.&#xD;
      68GA-PSMA-11 is an imaging radioactive drug that can target this molecule in tissues for&#xD;
      imaging and therapy of prostate cancer. Food substances, such as monosodium glutamate, may&#xD;
      reduce salivary gland uptake of 68GA-PSMA-11. Ultimately, giving MSG may reduce potential&#xD;
      harm and injury to the salivary glands in patients with prostate cancer treated with&#xD;
      PSMA-targeted molecular radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the effect of monosodium glutamate (MSG) administration (glutamate&#xD;
      supplementation) on the salivary gland uptake of gallium Ga 68-labeled PSMA-11&#xD;
      (68Ga-PSMA-11).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the effect of MSG administration on renal 68Ga-PSMA-11 uptake. II. To&#xD;
      determine the effect of MSG administration on tumor 68Ga-PSMA-11 uptake. III. To determine if&#xD;
      68GA-PSMA-11 is excreted in the saliva. IV. Safety of MSG administration both oral ingestion&#xD;
      and oral-salivary stimulation.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      Arm I: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) and undergo a&#xD;
      positron emission tomography (PET)/computed tomography (CT) scan on day 1. Within 2 weeks&#xD;
      (days 2-14), patients receive MSG orally (PO) over 10 minutes and receive a second dose of&#xD;
      gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo&#xD;
      collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection&#xD;
      and 90 minutes after PET/CT.&#xD;
&#xD;
      Arm II: Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1.&#xD;
      Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11&#xD;
      IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a&#xD;
      total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of&#xD;
      saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes&#xD;
      after PET/CT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">May 6, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary gland uptake of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11)</measure>
    <time_frame>2 measurements within 2 to 14 days maximum (on positron emission tomography [PET]1 and PET2)</time_frame>
    <description>Standard uptakes values (SUV) values (maximum SUV [SUVmax] and SUVmean) in all assessable salivary glands will be measured with a spherical volume-of-interest with and without the administration of monosodium glutamate (MSG) interventions. SUVmax/salivary gland will be calculated and a mean SUVmax/patient will be generated. The aim is to show a 2-fold reduction of the salivary gland 68Ga-PSMA-11 uptake after MSG administration. Paired T-test will be used to determine statistical significance per salivary gland and per patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal 68Ga-PSMA-11 uptake</measure>
    <time_frame>2 measurements within 2 to 14 days maximum (on PET1 and PET2)</time_frame>
    <description>SUVmax and SUVmean in the kidneys will be measured with a spherical volume-of-interest with and without the administration of MSG interventions. SUVmax/kidneys will be calculated and a mean SUVmax/patient will be generated. Paired T-test will be used to determine statistical significance per salivary gland and per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor 68Ga-PSMA-11 uptake</measure>
    <time_frame>2 measurements within 2 to 14 days maximum (on PET1 and PET2)</time_frame>
    <description>SUVmax and SUVmean in the visible tumor lesions will be measured with a spherical volume-of-interest with and without the administration of MSG interventions. SUVmax/tumor lesions will be calculated and a mean SUVmax/patient will be generated. Paired T-test will be used to determine statistical significance per salivary gland and per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva radioactivity concentration</measure>
    <time_frame>2 measurements within 2 to 14 days maximum (on PET1 and PET2)</time_frame>
    <description>Saliva radioactivity concentration will be compared with and without saliva stimuli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of MSG administration</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of saliva</description>
    <arm_group_label>Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_label>Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_label>Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_label>Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Monosodium Glutamate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_label>Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <other_name>MSG Monohydrate</other_name>
    <other_name>Sodium Glutamate Monohydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <arm_group_label>Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>positron emission tomography scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient volunteer to undergo 2 PSMA PET/CT scans within 14 days&#xD;
&#xD;
          -  Histopathologically proven prostate cancer (PCa)&#xD;
&#xD;
          -  PSMA PET/CT indicated for :&#xD;
&#xD;
               -  Initial staging before definitive therapy&#xD;
&#xD;
               -  Biochemical recurrence localization&#xD;
&#xD;
               -  Metastatic disease re-staging&#xD;
&#xD;
          -  Ability to understand a written informed consent document and the willingness to sign&#xD;
             it&#xD;
&#xD;
          -  Ability to ingest 300 mL of fluid across 10 minute period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior salivary gland surgery or radiation therapy&#xD;
&#xD;
          -  Prior history or current salivary gland disease&#xD;
&#xD;
          -  Unable to lie flat, still or tolerate a PET scan&#xD;
&#xD;
          -  Unable to follow the salivary flow stimuli administration regimen&#xD;
&#xD;
          -  Unable to follow the glutamate supplementation administration regimens&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and&#xD;
             diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg,&#xD;
             or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension&#xD;
             under medication are eligible&#xD;
&#xD;
          -  Sodium/salt restricted diet due to other medical conditions&#xD;
&#xD;
          -  History of severe asthma that has led to hospitalizations or emergency room visits&#xD;
&#xD;
          -  History of severe contraindications to MSG consumption including severe headaches,&#xD;
             migraines or other intolerance&#xD;
&#xD;
          -  Change to treatment administered between time of baseline scan and MSG scan&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

